Praecis Seeks Plenaxis Coverage Decision To Cement Prescriber Base
Executive Summary
Praecis believes a Medicare national coverage determination for Plenaxis will help overcome reluctance among prescribers to supply the prostate cancer drug to patients
You may also be interested in...
Praecis Plenaxis Medicare Coverage Policy Limits Payment To Approved Uses
The Centers for Medicare & Medicaid Services national coverage decision for Praecis' prostate cancer drug Plenaxis restricts reimbursement to within FDA approved uses
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011